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including pain, spinal cord compression, hypercalcemia, 
and pathologic fractures. The proper care of patients with 
bone metastasis requires interdisciplinary treatment deliv-
ered by orthopedic surgeons, radiation oncologists, medi-
cal oncologists, pain medicine specialists, radiologists, 
and palliative care professionals. Radiotherapy (RT) can 
provide successful palliation of painful bone metastasis in 
50–80 % of patients in a time efficient manner, and is asso-
ciated with very few adverse effects, allowing complete 
pain relief at the treated site in up to one-third of patients 
[1]. Recently, in the field of radiation oncology, emerging 
novel techniques have been developed and adapted for the 
treatment of bone metastases. In light of these advances, 
the focus of this review includes the efficacy of RT, new RT 
methods, and relevant prognostic factors. The significance 
of each of these in the management of spinal bone metasta-
ses is discussed.
Radiation dose and schedule
RT is commonly used to provide pain relief in cases of 
painful bone metastases. Chow et al. [2] conducted a meta-
analysis of 25 randomized palliative RT trials for uncompli-
cated painful bone metastases comparing 8 Gy in single and 
20–30 Gy in multiple fractions. They concluded that both 
the overall pain relief rate (60 % in the single-fraction arm 
and 61 % in the multiple-fraction arm) and the complete 
pain relief rate (23 and 24 %, respectively) were similar with 
no significant difference between these schedules. Although 
retreatment rates were higher in those who received single-
fraction therapy, 8 Gy in single-fraction RT was suggested 
as the standard of care for the palliation of uncomplicated 
painful bone metastases in the recent American Society for 
Therapeutic Radiology and Oncology guidelines [3].
Abstract The management of spinal bone metastases is com-
plex. In this review, the efficacy, methodology, and utilization 
of radiotherapy (RT) for spinal bone metastases are discussed. 
A number of randomized trials have evaluated the efficacy of 
8 Gy, single-fraction RT for the palliation of painful bone metas-
tases. However, RT for metastatic spinal cord compression has 
not been evaluated with respect to its optimal dose, palliative 
potential, or its ability to improve motor function. Two highly 
sophisticated RT techniques — stereotactic body RT (SBRT) 
and intensity-modulated RT (IMRT) — have recently been 
adapted for the treatment of spinal bone metastases, and both 
have the potential to achieve excellent control while minimizing 
acute and late toxicity. SBRT and IMRT are particularly well 
suited for the treatment of spinal bone metastases when they 
are localized or require re-irradiation, and may provide superior 
tumor control. Predicting the prognosis of patients with bone 
metastases and assessing spinal instability are both important 
when selecting the optimal RT method and deciding whether 
to perform surgery. The proper care of spinal bone metastases 
patients requires an interdisciplinary treatment approach.
Introduction
Bone metastases are a common manifestation of malig-
nancy that can cause severe and debilitating effects, 
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It is possible that patients with metastatic spinal cord 
compression (MSCC) will benefit more from higher-dose 
multiple-fraction RT than they would from lower-dose 
single-fraction RT, although currently, there is little data to 
support this (Table 1). In their review, Chow et al. [1] found 
that spinal cord compression occurred in 5.7 and 4.1 % of 
patients who received single-fraction and multiple-fraction 
RT, respectively. Although there was a trend favoring mul-
tiple-fraction RT, this did not reach statistical significance 
(P = 0.31). Rades et al. [4] evaluated the local control 
achieved using different RT schedules for MSCC. In their 
prospective, non-randomized study, local control was found 
to be significantly better after a long course of treatment 
(30 Gy in 10 fractions, 37.5 Gy in 15 fractions, and 40 Gy 
in 20 fractions) compared to a shorter course (8 Gy in a sin-
gle-fraction, and 20 Gy in 4 fractions). In contrast, Maran-
zano et al. [5] demonstrated that a single-fraction RT was 
sufficient, and resulted in only minimal toxicity for patients 
with a poor prognosis.
Rades et al. [6] suggested in their retrospective study 
that dose escalation beyond 30 Gy in 10 fractions did not 
improve motor function and local control of MSCC in radi-
oresistant tumors, such as renal cell carcinoma, colorec-
tal cancer, and malignant melanoma. However, in another 
report [7], dose escalation beyond 30 Gy was found to give 
better local control and extend overall survival in patients 
with breast cancer, prostate cancer, myeloma/lymphoma, 
and others who had a favorable prognosis. Thus, 30 Gy in 
10 fractions could be regarded as the standard therapeutic 
dose for MSCC. Although the available evidence is limited, 
dose escalation beyond 30 Gy may improve local control 
and overall survival in patients with a favorable survival 
prognosis, but it may not improve functional outcome, and 
dose escalation to 40 Gy in 20 fractions may still be insuf-
ficient for radioresistant tumors.
IMRT and stereotactic body RT
Recently, two sophisticated RT techniques, stereotactic 
body RT (SBRT; including stereotactic radiosurgery and 
stereotactic RT) and intensity-modulated RT (IMRT) have 
been adapted for the treatment of spinal bone metastases. 
SBRT uses more beams from many more directions than 
conventional opposed-field RT and consequently delivers 
much higher doses in a hypofractionated manner (either as 
a single fraction or as a smaller number of fractions). IMRT 
makes it possible to deliver optimal radiation doses safely 
to an irregularly shaped target while minimizing the dose 
to the surrounding normal structures. In order to achieve 
a high standard of targeting precision, these approaches 
require that the exact location and shape of the tumor be 
determined using imaging techniques (Fig. 1). In general, 
the term “spinal SBRT” refers to the use of both IMRT 
techniques and SBRT. The most important additional ben-
efit of spinal SBRT is the possibility of achieving excel-
lent dose coverage of the target, while avoiding the spinal 
cord, which is often the major limiting factor when deliver-
ing high-dose RT (Figs. 1, 2). Multiple retrospective stud-
ies have demonstrated that SBRT could feasibly be used 
to treat spinal metastases, and could control target lesions 
with only low toxicity [8, 9]. The local control rate based 
on imaging and/or pain management criteria was reported 
to be greater than 80 %, with only rare cases of toxicity.
Table 1  Outcomes of conventional RT for MSCC
RT radiotherapy, MSCC metastatic spinal cord compression, LC local control, RCT randomized controlled trial, Fr fraction, NA not available
References Study  
design
State of 
disease
Dose Ambulatory 
rate before 
treatment (%)
Motor function 
improvement (%)
LC Overall  
survival
Maranzano [5] RCT Unfavorable 
prognosis
8 Gy/1 Fr 64 12 NA 4 months 
(median)
16 Gy/2 Fr 67 21 NA 4 months 
(median)
Rades [4] Prospective 
non-RCT
Various 8 Gy/1 Fr, 20 Gy/4 Fr 61 37 61 % at 1 years 23 % at 1 year
30–40 Gy/10–20 Fr 62 39 81 % at 1 years 30 % at 1 year
Rades [7] Matched  
cohort
Favorable 
prognosis
30 Gy/10 Fr 85 40 71 % at 2 years 53 % at 2 years
37.5 Gy/15 Fr 40 Gy/20 Fr 85 41 92 % at 2 years 68 % at 2 years
Rades [6] Retrospective Radio-resist-
ant tumor
30 Gy/10 Fr 62 18 76 % at 1 year NA
37.5 Gy/15 Fr 40 Gy/20 Fr 63 22 80 % at 1 year NA
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Fig. 1  Upper panels the CyberKnife apparatus (left); a 3-dimen-
sional rendered image (right) blue lines indicate beam direc-
tions. Lower panels Xsight, the image-guidance system used in the 
CyberKnife system, enables the automatic tracking of skeletal struc-
tures (left). Representative dose distribution (right)
Fig. 2  Comparison of radiation dose distributions between conven-
tional radiotherapy (left) and intensity-modulated radiotherapy (right). 
Each colored line indicates an isodose curve. A higher radiation dose 
is concentrated on the vertebral bone metastasis while avoiding the 
heart and lungs (right)
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The indication and appropriateness of SBRT in the treat-
ment of spinal bone metastases should be carefully consid-
ered. The published efficacy and safety data for SBRT have 
mostly been from retrospective, single institution studies. 
Neither the exact dosing and target delineation require-
ments, nor the most appropriate inclusion and exclusion 
criteria for SBRT have been fully defined. In most previous 
studies of spinal SBRT, the primary endpoint for efficacy 
was the local control rate based on imaging and/or pain 
control, while motor function and ambulatory status were 
rarely considered. In their guidelines for RT of bone metas-
tasis, Lutz et al. [3] suggested that SBRT might be use-
ful for treating spinal bone metastases, although they also 
advised that this should preferably be within the confines of 
a clinical trial.
Postoperative irradiation
Surgery plays an important role in the management of 
patients with symptomatic MSCC. For patients with 
severe MSCC, Patchell et al. [10] demonstrated that surgi-
cal decompression was beneficial in the only randomized, 
multi-institutional trial to date. Significantly more patients 
who underwent surgery plus postoperative RT regained the 
ability to walk compared to those who only received RT. 
Patients treated with surgery also retained the ability to 
walk significantly longer than those treated with RT alone. 
Moreover, surgery only restored the ability to walk in 30 % 
of patients who failed to respond to earlier RT, which com-
pares unfavorably with the 62 % post-treatment ambulatory 
rate of the patients who were originally not able to walk 
and received surgery as their first treatment. Based on these 
findings, the authors claimed that surgery plus RT was the 
best first-line treatment for MSCC. However, this result 
conflicts with the findings of Rades et al. [11], who showed 
that surgery plus RT for MSCC patients with various pri-
mary tumors did not significantly improve their functional 
outcome compared to RT alone. They also showed that sur-
gery was beneficial for patients with relatively radioresist-
ant primary tumors [12] (Table 2).
Although the exact criteria for surgery in MSCC patients 
continue to be debated, the following are generally agreed 
to be necessary: a favorable survival prognosis, a good 
performance status, a relatively radioresistant tumor type, 
and MSCC accompanied with mechanical instability [13, 
14]. RT alone is recommended for MSCC from highly 
radiosensitive tumors, such as hematological malignan-
cies and germ cell tumors. A dose of 30 Gy in 10 fractions 
for MSCC in a postoperative setting is the most frequently 
used and is now considered to be the standard treatment 
[10–12]. Higher doses may also be administered to patients 
with a favorable prognosis. However, these doses are based Ta
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on the use of RT alone for MSCC, and there are no reports 
comparing optimal postoperative RT doses.
A number of retrospective reports have focused on 
the postoperative efficacy of SBRT in MSCC patients 
(Table 3). The study with the largest cohort, by Laufer 
et al. [16], reported that high-dose hypofractionated SBRT 
provided better local tumor control compared with low-
dose hypofractionated SBRT. Epidural disease is one of 
the major factors limiting the efficacy of spinal SBRT. Al-
Omair et al. [17] showed that epidural disease progression 
was the most common treatment failure after spinal SBRT, 
and postoperative epidural disease grade was a significant 
predictor of local control. Ideally, in order to administer a 
tumoricidal radiation dose by SBRT more safely, it may 
be possible to create a small margin of 2–3 mm between 
the tumor and the spinal cord by performing separation 
surgery. This allows a full dose to be administered to the 
entire tumor volume while minimizing the radiation expo-
sure to the spinal cord. A treatment approach reported by 
Bate et al. [18] that included SBRT alone for patients with 
minimal MSCC, and separation surgery followed by SBRT 
for patients with high-grade MSCC, seems a reasonable 
strategy.
Re‑irradiation of spinal bone metastases
Notably, re-irradiation is effective in improving or main-
taining motor function. Rades et al. [19] conducted a retro-
spective study of re-irradiation for MSCC, and found that 
motor function improved in 36 % of patients, was stable 
in another 50 % of patients, and deteriorated in 14 % of 
patients, and that there were no cases of late toxicity, such 
as radiation myelopathy. The degree of motor function 
after re-irradiation was associated with the effectiveness of 
the initial RT, performance status, time to development of 
motor deficits, and visceral metastases, whereas the re-irra-
diation schedule had no significant impact. A recent mul-
ticenter, randomized trial [20] of re-irradiation for painful 
bone metastases, of which 28 % were in the spine, showed 
that treatment with 8 Gy in a single fraction was as effec-
tive as, and less toxic than 20 Gy in multiple fractions; 
however, these findings were not robust in per-protocol 
analysis.
SBRT is well suited for re-irradiation of the spine and 
may provide superior tumor control compared to con-
ventional techniques, with reported local control rates 
of 66–93 % [21–23] (Table 4). Several studies identified 
potential risk factors for local recurrence after re-irradiation 
by spinal SBRT. Garg et al. [21] reported in their prospec-
tive study of spinal re-irradiation by SBRT that 13 of 16 
patients with local progression after SBRT had tumors 
within 5 mm of the spinal cord, and 6 of them eventually 
developed MSCC. Damast et al. [22] studied the dose–
response with SBRT used for re-irradiation, and found that 
there were significantly fewer local failures after SBRT 
with 30 Gy in 5 fractions compared to 20 Gy in 5 fractions.
Relatively little is known regarding the long-term toxici-
ties of re-irradiation. Because re-irradiation has the poten-
tial to exceed normal tissue tolerance, care must be taken 
when the re-irradiated volume contains the spinal cord, and 
it might be appropriate to sum the biologically effective 
Table 3  Outcomes of postoperative SBRT or SBRT alone for MSCC
SBRT stereotactic body radiotherapy, MSCC metastatic spinal cord compression, LC local control, Fr fraction, NA not available
References Patients/
lesions
Re-
RT
Treatment Dose Neurological response Postop 
MSCC
LC at 
1 year
Ryu [15] 62/85 0 SBRT alone 12–20 Gy/1 Fr Remained intact in 94 %, improved in 52 %, 
stable in 11 %, progression in 16 %
NA NA
Laufer [16] 186 0 Surgery + SBRT NA 11 % 83.6 %
109 75 18–36 Gy/5–6 Fr 77.4 %
37 14 24–30 Gy/3 Fr 95.9 %
40 2 24 Gy/1 Fr 91 %
Al-Omair [17] 80 0 Surgery + SBRT NA 10 % 84 %
35 0 18–26 Gy/1–2 Fr 100 %
45 0 18–40 Gy/3–5 Fr 70 %
Bate [18] 57/69 0 NA 94.2 %
21 lesions 6 Surgery + SBRT 16–23 Gy/1 Fr, 
20–30 Gy/3–5 Fr
Frankel score improved in 14 %, stable in 
81 %, and declined in 5 %
90.5 %
48 lesions 24 SBRT alone 16–23 Gy/1 Fr 
20–30 Gy/3–5 Fr
Frankel score improved in 10 %, and stable  
in 90 %
95.8 %
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doses (BEDs) from the initial and repeat treatment regi-
mens in order to estimate the risk of radiation myelopathy 
[3]. Radiation-induced myelopathy can occur 3–25 months 
after RT [24, 25], although complications associated with 
spinal re-irradiation are only rarely reported. Higher cumu-
lative RT doses (BED > 135.5 Gy2), higher doses of each 
RT course (BED > 98 Gy2), and a short interval between 
the courses (<6 months) could be associated with a higher 
probability of developing radiation-induced myelopathy 
[24].
Assessment for spinal instability in the treatment 
of spinal bone metastases
Spinal instability is associated with the development of 
neurologic deficits, mechanical pain, and progressive 
deformity [26]. Therefore, early recognition of impending 
instability may prevent painful collapse and loss of func-
tion by prompting timely referral and treatment. In order 
to create a simple, standardized referral tool for non-spine 
specialists, the Spine Oncology Study Group developed 
the spinal instability neoplastic score (SINS) [26], which 
is based on clinical and radiologic findings. Huisman et al. 
[27] showed that a higher SINS increased the risk of RT 
failure in patients with spinal metastases, independent of 
the performance status, primary tumor type, and symptoms. 
They hypothesized that metastatic spinal bone pain, pre-
dominantly caused by mechanical instability, responds less 
well to RT than pain that results mainly from local tumor 
activity.
Vertebral fracture is common after RT for metastatic 
spine lesions (Fig. 3). Rose et al. [28] demonstrated that 
lytic disease involving more than 40 % of the vertebral 
body and located at or below T10 confers a high risk of 
fracture, with correspondingly poorer clinical outcomes. 
Sahgal et al. [29] reported the results of the first multi-
institutional study of SBRT-induced vertebral compression 
fractures (VCFs), including whether the SINS can predict 
this adverse event. The crude risk of fracture was 14 %, 
the median time to VCF was 2.5 months, and the majority 
(65 %) of VCFs occurred in the first 4 months following 
SBRT. Moreover, multivariable analysis identified dose 
per fraction (greatest risk for ≥20 Gy), in addition to 3 of 
the 6 original SINS criteria: baseline VCF, a lytic tumor, 
and spinal deformity, as significant predictors of VCF. 
In a review of SBRT-induced VCF, 11–47 % of patients 
who developed VCFs needed a salvage spinal reconstruc-
tion procedure, such as percutaneous cement augmen-
tation procedures or open spinal reconstructive surgery 
[30]. These results may help clinicians identify high-risk 
patients who would benefit from prophylactic vertebro- or 
kyphoplasty.Ta
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Conclusion
RT is typically the mainstay of treatment for spinal bone 
metastases. A number of studies have shown that palliative 
RT can be effective for painful bone metastases, while rela-
tively little is known about the management of spinal bone 
metastases, especially MSCC. The management of MSCC 
requires a consideration of motor function and spinal insta-
bility as well as pain and local control. SBRT can safely 
administer a higher dose to the target, and can potentially 
provide lasting local control. SBRT is a promising method; 
however, epidural recurrence after SBRT and SBRT-
induced VCF continue to be problematic, and require the 
appropriate application of combination SBRT and surgery. 
An evaluation of functional outcomes following spinal 
SBRT and the identification of indicators for surgery are 
needed to establish an optimal treatment strategy for spinal 
metastases.
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